Intelligence · Clinical pipeline
Metabolic & obesity R&D Pipeline
GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.
Quick answer
Metabolic & obesity: NovaPharmaNews indexes 744 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.
Top sponsors
- Takeda 75 programs
- NovoThirteen 61 programs
- First People's Hospital 38 programs
- Regeneron UK 35 programs
- Eli Lilly and 29 programs
- Chinese Academy of 26 programs
- United Therapeutics Europe 24 programs
- Boehringer Ingelheim 19 programs
- Anaxis Pharma 18 programs
- LEXICON PHARMACEUTICALS 16 programs
- George Institute for 15 programs
- Novo Nordisk A/S 14 programs
Pipeline programs
-
Insulin Glargine
Sanofi Pasteur
Diabetes Mellitus, Type 2
2 trials -
Insulin Glargine
Eli Lilly and Company
Diabetes Mellitus, Type 2
1 trial -
Insulin glulisine
Sanofi Pasteur
Diabetes Mellitus, Type 1
1 trial -
Insulin lispro low mixture
Eli Lilly and Company
Type 2 Diabetes Mellitus
1 trial -
Intravenous Ibuprofen
CUMBERLAND PHARMACEUTICALS INC
Obesity
1 trial -
Intravitreal Aflibercept
Regeneron UK Limited
Diabetic Macular Edema
2 trials -
Liraglutide
Sana Biotechnology
Morbid Obesity
1 trial -
Lixisenatide (AVE0010)
Sanofi Pasteur
Diabetes Mellitus, Type 2
3 trials -
Maggot debridement therapy
The First People's Hospital of Lianyungang
Diabetic Foot Ulcers
1 trial -
Metformin
Takeda
Type 2 Diabetes Mellitus
1 trial -
Mounjaro solution for injection in pre-filled... for Obesity
The George Institute
Obesity
1 trial -
Mysimba 8 mg/90 mg prolonged-release tablets
Disc Medicine
Obesity, Obesity Surgery
1 trial -
NESINA ACT TAB. 25/15mg
Takeda
Diabetes
1 trial -
NN1436-7727
NovoThirteen
Type 2 diabetes
1 trial -
NN9536-7752
NovoThirteen
Obesity
1 trial -
NN9838-4968
NovoThirteen
Obesity and T2D
1 trial -
Nocardia rubra Cell Wall Skeleton
The First People's Hospital of Lianyungang
Diabetic Foot Ulcer
1 trial -
Optimal hypoglycemic treatment
The First People's Hospital of Lianyungang
Type2 Diabetes
1 trial -
PI24/01356
The George Institute
Type 2 diabetes
1 trial -
Pharmacotherapy
The First People's Hospital of Lianyungang
Diabetes Mellitus, Type 2
1 trial -
Pioglitazone
Takeda
Obesity
1 trial -
Pioglitazone
Takeda
Diabetes Mellitus
9 trials -
Pioglitazone
Takeda
Diabetes Type 2
1 trial -
Pioglitazone
Takeda
Type II Diabetes Mellitus
1 trial -
Pioglitazone
Takeda
Metabolic Syndrome
1 trial -
Pioglitazone
Takeda
Diabetes Mellitus, Type 2
2 trials -
Pioglitazone and Metformin
Disc Medicine
Diabetes Mellitus, Type 2
1 trial -
Pioglitazone and insulin
Takeda
Diabetes Mellitus
2 trials -
Pioglitazone and metformin
Takeda
Diabetes Mellitus
5 trials -
Pioglitazone then Placebo
Takeda
Diabetes
1 trial -
Placebo of vildagliptin
Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
1 trial -
Plasma rich in growth factors
Wuhan Createrna Science and Technology Co., Ltd
Foot ulcers in diabetic patients with peripheral arterial disease
1 trial -
Pregabalin
Yung NA
Diabetic Peripheral Neuropathy
1 trial -
R0126321A
Disc Medicine
Diabetic foot ulcer
1 trial -
RIMEGEPANT , Capsaicin
Disc Medicine
Obesity, Migraine
1 trial -
Rapid Acting insulin with pre-treatment of rHuPH20
HALOZYME THERAPEUTICS, INC.
Type 1 Diabetes Mellitus
1 trial -
Renin-angiotensin system blockers
Hospital Authority, Hong Kong
Diabetes
1 trial -
SGLT2 inhibitor
The First People's Hospital of Lianyungang
Type2 Diabetes
1 trial -
SGLT2 inhibitor (Empagliflozin 25 MG)
Hospital Authority, Hong Kong
Type2 Diabetes
1 trial -
SIMA SPK 01
The George Institute
End-stage kidney disease in Type 1 diabetes, SIROLIMUS VERSUS MYCOPHENOLATE MOFETIL IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE RISK OF HERNIA
1 trial -
Semaglutide
United Therapeutics Europe Ltd
Obesity
1 trial -
Semaglutide B 3.0 mg/ml PDS290
Disc Medicine
obesity
1 trial -
Sham Injection
HALOZYME THERAPEUTICS, INC.
Type 1 Diabetes Mellitus
1 trial -
Simvastatin
Hospital Authority, Hong Kong
Obesity
1 trial -
Sitagliptin
Chen Suning
Type 2 Diabetes
1 trial -
Subcutaneous glargine insulin
Lxo Ireland Designated Activity Company
Diabetes Mellitus
1 trial -
TRS-2019-00002051
Wuhan Createrna Science and Technology Co., Ltd
Type 2 diabetes mellitus
1 trial -
Tirzepatide
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus
1 trial
Frequently asked questions
How many metabolic & obesity pipeline programs are tracked?
744 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.